Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) – comparison of adverse event risks in randomized controlled trials
Analyses of adverse events (AEs) are an important aspect of benefit-risk and health-technology assessments of therapies. The SAVVY project aims to improve the analyses of AE data in clinical trials through the use of survival techniques appropriately dealing with varying follow-up times and competing events (CEs). In an empirical study including randomized clinical trials (RCT) from several sponsor organisations the effect of varying follow-up times and CEs on comparisons of two treatment arms with respect to AE risks is investigated. CEs definition does not only include death before AE but also end of follow-up for AEs due to events possibly related to the disease course or safety of the treatment. The comparisons of relative risks (RRs) of standard probability-based estimators to the gold-standard Aalen-Johansen estimator (AJE) or hazard-based estimators to an estimated hazard ratio (HR) from Cox regression are done descriptively, with graphical displays, and using a random effects meta-analysis. The influence of different factors on the size of the bias is investigated in a meta-regression. Ten sponsors provided 17 RCTs including 186 types of AEs. We confirm for estimation of the RR concerns regarding incidence densities: the probability transform incidence density ignoring CEs performed worst. However, accounting for CEs in an analysis that parametrically mimicked the non-parametric AJE performed better than both one minus Kaplan-Meier and AJE that only considered death as a CE. The analysis based on hazards revealed that the incidence density underestimates the HR of AE and CE of death hazard compared to the gold-standard Cox regression. Both the choice of the estimator of the AE probability and a careful definition of CEs are crucial in estimation of RRs. For RRs based on hazards, the HR based on Cox regression has better properties than the ratio of incidence densities.
READ FULL TEXT